Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2928372 | 0.96 | NPC1 (0.43) | NPC1RAB9AKDM4ERXFP1CYP1A2 | |
| SCHEMBL6379433 | 0.94 | NPC1 (0.44) | NPC1RAB9AKDM4ERXFP1KMT2A | |
| SCHEMBL4751934 | 0.83 | KMT2A (0.39) | NPC1RAB9AKDM4ERXFP1CYP1A2 | |
| SCHEMBL15273696 | 0.83 | ALDH1A1 (0.41) | CYP1A2KMT2AALDH1A1MAPK1MEN1 | |
| SCHEMBL2519257 | 0.82 | ALDH1A1 (0.39) | NPC1RAB9AKDM4ERXFP1CYP1A2 | |
| SCHEMBL6385372 | 0.82 | CYP1A2 (0.44) | NPC1RAB9AKDM4ERXFP1CYP1A2 | |
| SCHEMBL24812522 | 0.81 | RAB9A (0.37) | NPC1RAB9AKDM4ERXFP1CYP1A2 | |
| Hydrochloric Acid SCHEMBL16100186 | 0.81 | KMT2A (0.40) | NPC1RAB9AKDM4ERXFP1CYP1A2 | |
| SCHEMBL6384282 | 0.81 | FAAH (0.40) | NPC1RAB9AKDM4ERXFP1CYP1A2 | |
| SCHEMBL3309074 | 0.80 | CYP1A2 (0.40) | NPC1RAB9AKDM4ERXFP1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115873000-B | Isoquinolinones and quinazolinones compounds, and composition and application thereof | 中山医诺维申新药研发有限公司 | 2025-02-28 | — | — | CN | disclosed |
| US-11725008-B2 | Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-15 | — | — | US | disclosed |
| US-11725008-B2 | Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-15 | — | — | US | disclosed |
| US-11725008-B2 | Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-15 | — | — | US | disclosed |
| WO-2023051495-A1 | ISOQUINOLINONE AND QUINAZOLINONE COMPOUNDS, AND COMPOSITION AND USE THEREOF | 中山医诺维申新药研发有限公司 | 2023-04-06 | — | — | WO | disclosed |
| CN-115873000-A | Isoquinolone and quinazolinone compounds, and composition and application thereof | 中山医诺维申新药研发有限公司 | 2023-03-31 | — | — | CN | disclosed |
| WO-2023049199-A1 | AZOLE COMPOUNDS | ZENO MANAGEMENT, INC. (US) | 2023-03-30 | — | — | WO | disclosed |
| US-20230027126-A1 | ETHANEDIAMINE-HETEROCYCLE DERIVATIVES AS INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-01-26 | — | — | US | disclosed |
| US-20230027126-A1 | ETHANEDIAMINE-HETEROCYCLE DERIVATIVES AS INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-01-26 | — | — | US | disclosed |
| CN-108948019-B | Focal adhesion kinase inhibitors and uses thereof | 广东东阳光药业有限公司 | 2022-07-08 | — | — | CN | disclosed |
| EP-1626972-A1 | PROCESS FOR SYNTHESIZING ß-LACTAMASE INHIBITOR INTERMEDIATES | Wyeth Holdings Corporation (US) | 2006-02-22 | — | — | EP | disclosed |
| US-20050107412-A1 | Pharmaceutically active compounds | PFIZER INC | 2005-05-19 | — | — | US | disclosed |
| US-6831074-B2 | Inhibitors of cyclic guanosine 3',5'-monophosphate phosphodiesterases (cGMP PDES); for use in therapy of sexual disorders | PFIZER INC | 2004-12-14 | — | — | US | disclosed |
| WO-2004104006-A2 | PROCESS FOR SYNTHESIZING β-LACTAMASE INHIBITOR IN INTERMEDIATES | WYETH HOLDINGS CORPORATION (US) | 2004-12-02 | — | — | WO | disclosed |
| WO-2004104008-A1 | PROCESS FOR SYNTHESIZING β-LACTAMASE INHIBITOR INTERMEDIATES | WYETH HOLDINGS CORPORATION (US) | 2004-12-02 | — | — | WO | disclosed |
| US-20040242874-A1 | Process for synthesizing beta-lactamase inhibitor intermediates | WYETH HOLDINGS CORPORATION | 2004-12-02 | — | — | US | disclosed |
| US-20040229324-A1 | Production of bicyclic-heteroaryl-2-carboxylic acids by selective enzymatic hydrolysis of a mixture of positional esters | WYETH HOLDINGS CORPORATION | 2004-11-18 | — | — | US | disclosed |
| US-20040132708-A1 | Process for preparing 6-alkylidene penem derivatives | WYETH | 2004-07-08 | — | — | US | disclosed |
| US-20040077622-A1 | Bicyclic 5-alkylidene-penems as beta lactamases inhibitors | WYETH | 2004-04-22 | — | — | US | disclosed |
| US-20040053913-A1 | Process for preparing 6-alkylidene penem derivatives | WYETH | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132708-A1 | Process for preparing 6-alkylidene penem derivatives | PGM2, BPGM, MRPL21 | NPC1 800/4885RAB9A 1712/4885KDM4E 1977/4885 |
| US-20050107412-A1 | Pharmaceutically active compounds | PDE5A, PDE2A, PDE3B | NPC1 3153/4885RAB9A 436/4885KDM4E 1687/4885 |
| US-11725008-B2 | Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases | PRMT1, PRMT5, PRMT3 | NPC1 4115/4885RAB9A 1755/4885KDM4E 78/4885 |
| US-20040229324-A1 | Production of bicyclic-heteroaryl-2-carboxylic acids by selective enzymatic hydrolysis of a mixture of positional esters | COASY, CES2, CES1 | NPC1 2911/4885RAB9A 1857/4885KDM4E 598/4885 |
| US-20040053913-A1 | Process for preparing 6-alkylidene penem derivatives | PGM2, BPGM, MRPL21 | NPC1 800/4885RAB9A 1712/4885KDM4E 1977/4885 |
| US-20040077622-A1 | Bicyclic 5-alkylidene-penems as beta lactamases inhibitors | PGLS, BPGM, B2M | NPC1 1173/4885RAB9A 1874/4885KDM4E 957/4885 |
| US-20040242874-A1 | Process for synthesizing beta-lactamase inhibitor intermediates | COASY, DCXR, MGAM | NPC1 3667/4885RAB9A 1763/4885KDM4E 612/4885 |
| US-20230027126-A1 | ETHANEDIAMINE-HETEROCYCLE DERIVATIVES AS INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASES | PRMT1, PRMT5, PRMT3 | NPC1 4115/4885RAB9A 1755/4885KDM4E 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.